2017
DOI: 10.4103/sajc.sajc_181_17
|View full text |Cite
|
Sign up to set email alerts
|

Oncology gold standard® practical consensus recommendations for the use of monoclonal antibodies in the management of squamous cell carcinoma of head and neck

Abstract: We present the 2017 Oncology Gold Standard Practical Consensus Recommendation for use of monoclonal antibodies in the management of advanced squamous cell carcinoma of head neck region.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2

Citation Types

0
3
0

Year Published

2018
2018
2023
2023

Publication Types

Select...
3

Relationship

0
3

Authors

Journals

citations
Cited by 3 publications
(3 citation statements)
references
References 41 publications
0
3
0
Order By: Relevance
“…Guidelines and recommendations for the treatment and management of patients with SCCHN in Asia have been published for India, 17,18 China, 19 Japan, 20 Malaysia 21 and Taiwan 22 and are important for the standardisation of both diagnostic and treatment approaches, with the aim of optimising clinical outcomes for what is an increasing health care problem in Asia. The European Society for Medical Oncology (ESMO) guidelines for the diagnosis treatment and follow-up of patients with SCCs of the oral cavity, larynx, oropharynx and hypopharynx (excluding nasopharyngeal carcinomas), prepared in conjunction with the European Head and Neck Society (EHNS) and the European Society for Radiotherapy and Oncology (ESTRO), were published in October 2020, 23 and a decision was taken by ESMO and the Korean Society of Medical Oncology (KSMO) that these guidelines should be adapted for patients of Asian ethnicity.…”
Section: Introductionmentioning
confidence: 99%
“…Guidelines and recommendations for the treatment and management of patients with SCCHN in Asia have been published for India, 17,18 China, 19 Japan, 20 Malaysia 21 and Taiwan 22 and are important for the standardisation of both diagnostic and treatment approaches, with the aim of optimising clinical outcomes for what is an increasing health care problem in Asia. The European Society for Medical Oncology (ESMO) guidelines for the diagnosis treatment and follow-up of patients with SCCs of the oral cavity, larynx, oropharynx and hypopharynx (excluding nasopharyngeal carcinomas), prepared in conjunction with the European Head and Neck Society (EHNS) and the European Society for Radiotherapy and Oncology (ESTRO), were published in October 2020, 23 and a decision was taken by ESMO and the Korean Society of Medical Oncology (KSMO) that these guidelines should be adapted for patients of Asian ethnicity.…”
Section: Introductionmentioning
confidence: 99%
“…In view of the aforementioned drawbacks of the LAL assay and the high demand from food and pharmaceutical industries, substantial efforts are being made to design alternative endotoxin sensors that are direct, specific, and able to detect LPS repeatedly. Among the bioreceptors used in sensors to detect specific biotargets, antibodies are the gold standard ( 6 ). Nevertheless, antibodies are inherently unstable and have a costly and cumbersome synthesis process ( 7 ).…”
Section: Introductionmentioning
confidence: 99%
“…While the discussions took into consideration the scenario as exists in developing countries like India (as a representative country with limited resources), the final manuscript was to be applicable globally – a process that we have shown to be effective earlier. [ 2 3 4 ]…”
mentioning
confidence: 99%